Edition:
United Kingdom

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

14.35USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$14.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
35,729
52-wk High
$15.75
52-wk Low
$6.72

Chart for

About

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications... (more)

Overall

Beta: 0.21
Market Cap(Mil.): $225.49
Shares Outstanding(Mil.): 27.84
Dividend: --
Yield (%): --

Financials

  KIN.OQ Industry Sector
P/E (TTM): -- 85.69 32.76
EPS (TTM): -1.17 -- --
ROI: -34.47 1.78 14.61
ROE: -34.50 3.28 16.33

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

07 May 2018

UPDATE 1-FDA approves Kindred treatment for problem weight loss in cats

May 7 Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

07 May 2018

FDA approves Kindred's weight-loss ointment for cats

May 7 Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.

07 May 2018

BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement

* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING

07 May 2018

BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats

* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS

07 May 2018

BRIEF-Kindred Biosciences Announces Board Appointments

* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

25 Apr 2018

BRIEF-Kindred Biosciences Q4 Loss Per Share $0.35

* KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

01 Mar 2018

Earnings vs. Estimates